Comparison of the antigenemia assay and screening bronchoscopy for detection of cytomegalovirus infection after bone marrow transplantation
Cytomegalovirus (CMV) disease is one of the fatal complications after BMT and the best strategy for prophylaxis remains to be established. A pre-emptive therapy based upon CMV surveillance culture of bronchoalveolar lavage fluid (BALF) has decreased the incidence of CMV disease. 1 However, results of only surveillance bronchoscopy are insufficient to make a decision on initiating preemptive therapy because 22% of culture-negative patients have been found to develop CMV pneumonia through their clinical courses. 1 The antigenemia assay is another method of monitoring CMV infection and it is widely utilized in the management of CMV infection. It remains unknown, however, which is the more beneficial after BMT. In our institution, screening bronchoscopy and a weekly CMV antigenemia assay were initiated in 1993 and 1997, respectively. We performed a prospective study to evaluate the usefulness of screening bronchoscopy and antigenemia assay in the management of post-transplant CMV infection.
We prospectively examined 33 consecutive patients who received transplants between September 1997 and October 1998. There were 19 males and 14 females with a median age of 32 years (range 15-48). The details of CMV antigenemia and screening bronchoscopy were as previously described. 2 Surveillance bronchoscopy was performed on day 35 post-transplantation and BALF specimens were examined for CMV by shell vial culture 3 and by the polymerase chain reaction (PCR) method using CMV-specific primers. 4 We also performed CMV antigenemia assays weekly using monoclonal antibody (HRP-C7; Teijin Corporation, Tokyo, Japan) against pp65 antigen.
5 Ganciclovir was initiated when BALF samples were positive in the shell-vial culture and it was withheld regardless of the PCR results when the shellvial cultures were negative. Results of the CMV antigenemia assay were also taken into account on starting ganciclovir. We started ganciclovir either when more than 10 cells were found to be positive in the antigenemia assay in the case of transplantation from related donors or when a single cell was found to be positive or corticosteroid treatment had been initiated in the case of transplantation from unrelated donors. CMV infection was defined as detection of CMV in BALF by PCR and/or by shell vial culture or in blood by the CMV antigenemia assay. CMV disease was defined as demonstration of CMV in biopsy specimens on histology with associated clinical signs and symptoms.
Eighteen patients were diagnosed as having CMV infection and one patient was diagnosed as having CMV disease (CMV enterocolitis). All of them responded to ganciclovir and none died of CMV disease. We administered ganciclovir to 16 patients for the following reasons. In 10 cases, it was given based on the results of antigenemia assay and in the other six cases the patients received it because of initiation of corticosteroid therapy. No patient received it based upon the results of screening bronchoscopy. In eight cases, ganciclovir had been started before the screening bronchoscopy. In five of these eight cases, it was administered based on the results of the antigenemia assay and the other three patients received it at the time of initiation of steroid treatment.
When both the CMV antigenemia assay and screening bronchoscopy are performed together, the latter may not contribute to the decision as to whether to start ganciclovir and may be unnecessary for management of CMV infection after BMT. It is interesting that the incidence of positive findings in the shell vial culture of BALF specimens was reduced from 17% 2 to 0.5% in this study. This may indicate that early initiation of ganciclovir based on antigenemia assay findings and initiation of steroid treatment suppressed the reactivation of CMV in this study. The screening bronchoscopy is less sensitive in detecting CMV infection as compared to the antigenemia assay when the latter is performed routinely. Considering the sensitivity and invasiveness of the two methods of examination, the antigenemia assay seems to be more suitable for BMT recipients than does screening bronchoscopy.
In conclusion, the weekly antigenemia assay may be able to substitute for surveillance bronchoscopy after BMT, but our study has revealed some problems to be addressed. Firstly, the CMV antigenemia assay may be insufficient in some cases, because some may develop CMV disease without showing positive results in the antigenemia assay, even with weekly sampling. 6 Effective methods have not been established for these patients, but PCR of serum or whole blood samples may be promising because drawing of blood is less invasive than bronchoscopy and because PCR shows high sensitivity and high specificity in detecting CMV infection. Secondly, it remains unknown whether our criteria for the decision to start ganciclovir are adequate, although our conclusion is based on the validity of the criteria. At present, however, it seems impossible to discuss their validity, because the optimal criteria for starting ganciclovir have not been established and conventional criteria have been advocated without definite evidence. 7 Using these criteria, a number of patients who do not develop CMV disease may sustain unnecessary toxicity from ganciclovir. 7 Our criteria, modified from the previous report, 2 aim to identify patients at high-risk for CMV disease and to avoid the overuse of ganciclovir. We consider that little difference exists between our criteria and those of others for starting ganciclovir and that results of this study can be used by other institutions. 
